Genzyme Corporation v. Novartis Gene Therapies, Inc.
1:23-cv-00554
Overview
Parties
Defendant
Novartis Gene Therapies, Inc. Operating Company
Represented By
0 Attorneys ListedPlaintiff
Genzyme Corporation NPE (Individual / Inventor)
Represented By
0 Attorneys ListedCourt & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 4 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → | |
| π PCT International (WIPO) | PCT World Application | View Official Patent → | |
| πΊπΈ United States | US Continuation / Sibling | View Official Patent → |
Novartis Gene Therapies, Inc. et al. v. Aventis, Inc. et al.
Novartis Gene Therapies, Inc. et al. v. Genzyme Corporation et al.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US10429288
Analytical ultracentrifugation for characterization of recombinant viral particles
|
Filed: 2016-01-19
Issued: 2019-10-01
|
Active (9.2 yrs remaining)
Expires: 2036-01-19
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term; injunctive relief viable.
Standard Statutory Term β No obviousness-type double patenting noted.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. 4th Year Maintenance Fee Paid (8th Year Window Upcoming).